Gilead Sciences, Inc. generated $29.4B in FY2025 total revenue, including $20.8B from HIV products and $14.3B from Biktarvy. Led by Chairman and CEO Daniel P. O'Day, the company is using its antiviral cash engine to fund long-acting HIV prevention, oncology, and cell therapy growth.
Independent Editorial Analysis
9 historical events · Editorial analysis
Gilead Sciences Company Profile: Revenue, Business Model & Strategy
Research depth: 9 milestones · 8 FAQs
Gilead reported about $29.4B in FY2025 revenue and has about 17,000 employees. CEO Daniel P. O'Day leads the company; Michael L. Riordan founded or shaped...
Gilead is a biotechnology company known for HIV treatments, antiviral drugs, oncology medicines, cell therapies, and specialty pharmaceuticals. It reported about $29.4B in FY2025 revenue, was founded by Michael L. Riordan, and is led by CEO Daniel P. O'Day.
How Gilead Sciences makes money: Gilead makes money by discovering, developing, manufacturing, and commercializing patented medicines, with FY2025 revenue led by HIV therapies and supported by liver-disease, oncology, cell-therapy, and royalty/contract…
Annual Revenue (FY2025)$29.4B
Employees17,000
CEODaniel P. O'Day
Founded1987
IndustryTechnology
By Swet ParvadiyaLast reviewed:
In-Depth Analysis
Table of Contents
Gilead Sciences, Inc. Key Facts
Data Verified
| Company | Gilead Sciences, Inc. |
|---|---|
| Trajectory | Exponential |
| Financials | $29.4B (FY2025, last reviewed July 2026) [1] |
| Market Cap | $161.8B [2] |
| Net Income | $8.5B |
| Last reviewed | By Swet Parvadiya, Founder & Editor - May 2026 |
| Founded | 1987 |
| Founder(s) | Michael L. Riordan |
| CEO | Daniel P. O'Day |
| Headquarters | Foster City, California |
| Industry | Biotechnology |
| Employees | 17,000+ [3] |
Gilead Sciences Company Profile: Revenue, Business Model & Strategy
"Gilead Sciences, Inc. generated $29.4B in FY2025 total revenue, including $20.8B from HIV products and $14.3B from Biktarvy alone. Led by Chairman and CEO Daniel P. O'Day, the company is using that cash engine to fund long-acting lenacapavir prevention, Trodelvy, Kite cell therapy, and other pipeline assets while managing future HIV patent-cliff risk."
Why Gilead Sciences, Inc. Wins
Gilead Sciences, Inc. Wins customers and deals through its proprietary mastery of nucleotide analog chemistry and its associated global clinical data package in HIV, which offers a level of clinical efficacy and manufacturing scale that competitors cannot match. Biktarvy's ability to provide a once-daily, single-tablet regimen with a high genetic barrier to resistance has made it the standard of care for HIV treatment, supported by the most extensive clinical data package in the virology class. Additionally, the company's deep integration with academic medical centers through its clinical trial network provides physicians with access to advanced research and long-term safety data, creating a strong loyalty and preference for Gilead products in the infectious disease and oncology communities.
Gilead Sciences, Inc. operates in a competitive market alongside Pfizer Inc., AbbVie Inc., Moderna, Inc.. Analysts frequently compare Gilead Sciences, Inc. and Pfizer Inc. due to their overlapping products, target markets, and strategic positioning.
Gilead is a biotechnology company known for HIV treatments, antiviral drugs, oncology medicines, cell therapies, and specialty pharmaceuticals. It reported about $29.4B in FY2025 revenue, was founded by Michael L. Riordan, and is led by CEO Daniel P. O'Day.
Revenue
$29.4B
Founded
1987
Employees
17K+
Market Cap
$161.8B
Author: CorpDigest Research DeskVerified Accuracy
Explore Gilead Sciences In Depth
Detailed research across every dimension of Gilead Sciences — history, financials, leadership, and strategy.
Company History
The financial mechanics of this diversified model are exceptionally complex, requiring the simultaneous management of a high-volume, high-margin small molecule manufacturing network for HIV therapies, and a highly…
Full Gilead Sciences history →Revenue & Financials
Gilead Sciences reported $29.4B in revenue for fiscal year 2025. Data covers 4 fiscal years. Market capitalization stands at approximately $162B.
Gilead Sciences financials →Founders
Gilead Sciences was founded by Michael L. Riordan in 1987 in Foster City, California. Explore each founder's background, motivations, and their role in building the company.
Gilead Sciences founders →CEO & Leadership
Gilead Sciences is currently led by Daniel P. O'Day. Explore the full CEO history — leadership transitions, tenures, and the strategic decisions of each chief executive.
Gilead Sciences CEO history →Business Model
Gilead makes money by discovering, developing, manufacturing, and commercializing patented medicines, with FY2025 revenue led by HIV therapies and supported by liver-disease, oncology, cell-therapy, and royalty/contract…
How Gilead Sciences makes money →Acquisitions
Gilead Sciences has completed 4 documented acquisitions. Explore the full acquisition history and strategic rationale behind each deal.
Gilead Sciences acquisitions →Competitive Strategy
Gilead's growth strategy centers on extending its HIV leadership with long-acting lenacapavir, defending Biktarvy through lifecycle evidence, expanding liver-disease medicines, and scaling oncology through Trodelvy and…
Gilead Sciences strategy →Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions About Gilead Sciences
What was Gilead Sciences's revenue in FY2025?
Gilead Sciences reported $29.4 billion in FY2025 revenue. sales of HIV, oncology, liver-disease, and inflammation medicines provides Gilead Sciences's revenue.
How many employees does Gilead Sciences have?
Gilead Sciences employs about 17,000 people. Its workforce supports drug discovery, clinical trials, biopharma manufacturing, medical affairs, and commercial teams.
Who is Gilead Sciences's CEO?
Daniel P. O'Day is the CEO of Gilead Sciences. HIV leadership, oncology growth, pipeline execution, and capital allocation.
When was Gilead Sciences founded?
Gilead Sciences was founded in 1987 by its founding team in Foster City, California. Gilead grew from an antiviral developer into a major biopharmaceutical company with HIV and oncology franchises.
How does Gilead Sciences make money?
Gilead Sciences earns money through sales of HIV, oncology, liver-disease, and inflammation medicines. sales of HIV, oncology, liver-disease, and inflammation medicines provides Gilead Sciences's revenue.
What companies has Gilead Sciences acquired?
Gilead acquired Pharmasset, Kite Pharma, Immunomedics, and other biopharmaceutical businesses. Kite established Gilead in cell therapy while adding complex manufacturing and commercialization needs.
Is Gilead Sciences profitable?
Profitability depends on product mix, pricing, manufacturing, R&D productivity, and sales execution, alongside investment and operating discipline. HIV long-acting launches, oncology growth, pipeline data, pricing policy, and patent timelines.
Why is Gilead Sciences important?
Gilead is protecting its HIV franchise while building oncology and inflammation growth drivers. HIV expertise, antiviral science, global commercial reach, and cash generation.
Analysis: How Gilead Sciences, Inc. Makes Money
Deep dive into the Gilead Sciences, Inc. business model, revenue streams, and strategic moats in 2026.
Competitor Benchmarking
Compare
Financial data on this page is sourced from SEC EDGAR filings, official earnings releases, and verified press statements. Revenue figures are reviewed and updated periodically. Read our full data methodology ->
Primary source: www.sec.gov/Archives/edgar/data/882095/000088209526000006/gi
Explore More Brand Histories
This corporate intelligence report on Gilead Sciences, Inc. compiles data from verified filings. Explore more detailed brand histories and company histories in the global Biotechnology marketplace.
Editorial Methodology
Verified Analysis
Our research methodology involves cross-referencing SEC Edgar filings, official investor relations disclosures, and primary annual reports. We prioritize primary data over secondary media reports to ensure the highest degree of financial accuracy. Each profile is reviewed for editorial depth and word-count compliance (minimum 1,200 words) before publication.
1. Primary Sources
Every financial metric and strategic milestone is cross-referenced against official SEC filings (10-K, 10-Q), annual reports, and verified corporate press releases.
2. Expert Curation
Software tools help organize public data, then Swet Parvadiya reviews the narrative for strategic context, source quality, and clarity.
3. Multi-Pass Audit
Before publication, every intelligence report undergoes a technical audit for factual consistency, citation accuracy, and objective neutrality.
Explore Related Pages for Gilead Sciences, Inc.
Sources & References
The data and narrative synthesized in this intelligence report were verified against primary sources:
- [1]SEC EDGAR: Gilead Sciences, Inc. Annual Filings (10-K, 8-K)
- [2]Gilead Sciences, Inc. Corporate Website
- [3]Gilead Sciences, Inc. Annual Report 2025 - Revenue and Financial Data
- [4]sec.gov
- [5]investors.gilead.com
- [6]investors.gilead.com
- [7]data.sec.gov